# Safety and Efficacy of Secukinumab in Mild Psoriasis

> **NCT03131570** · PHASE2 · COMPLETED · sponsor: **James G. Krueger, MD, PhD** · enrollment: 23 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Secukinumab
- **DRUG:** Placebo followed by Secukinumab

## Key facts

- **NCT ID:** NCT03131570
- **Lead sponsor:** James G. Krueger, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-23
- **Primary completion:** 2020-01-08
- **Final completion:** 2021-06-21
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2022-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03131570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03131570, "Safety and Efficacy of Secukinumab in Mild Psoriasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03131570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*